Condition
Hereditary Amyloidosis, Transthyretin-Related
Total Trials
4
Recruiting
2
Active
3
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
Trial Status
Recruiting2
Completed1
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07124377RecruitingPrimary
Phenotypic Manifestations of Hereditary ATTR Amyloidosis
NCT05311488CompletedPrimary
Early Detection of Neuropathy in ATTRv
NCT06360289RecruitingPrimary
Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of the Transthyretin (TTR) Variants and Patients With Hereditary Transthyretin-mediated (hATTR) Amyloidosis With Polyneuropathy
NCT07080268Active Not Recruiting
Validation of a Questionnaire for Quality of Life Assessment in Patients With Transthyretin Amyloidosis.
Showing all 4 trials